{"component": "definition", "props": {"groups": [{"size": 3, "snippet": "means the general availability (on iOS, Google/Android and Web) of an updated version of the Truth Social app, with streaming enabled via the Master PoP at 1623 Farnam LLC\u2019s data center in Omaha, NE.", "samples": [{"hash": "cCMzVidbG1n", "uri": "/contracts/cCMzVidbG1n#milestone-i", "label": "Registration Rights Agreement (Trump Media & Technology Group Corp.)", "score": 35.6036949158, "published": true}, {"hash": "fhHMStmWTJd", "uri": "/contracts/fhHMStmWTJd#milestone-i", "label": "Registration Rights Agreement (Trump Media & Technology Group Corp.)", "score": 35.5023956299, "published": true}, {"hash": "bMXsB1Vr2ZJ", "uri": "https://s3.amazonaws.com/sec.irpass.cc/2660/0001140361-24-036636.pdf", "label": "s3.amazonaws.com", "score": 19.6024085218, "published": false}], "snippet_links": [{"key": "general-availability", "type": "definition", "offset": [10, 30]}, {"key": "updated-version", "type": "definition", "offset": [70, 85]}, {"key": "the-truth", "type": "definition", "offset": [89, 98]}, {"key": "data-center", "type": "definition", "offset": [174, 185]}], "hash": "1b784563bd3bb9ddc89384e4d974105e", "id": 1}, {"size": 2, "snippet": "The Phase I study is designed to allow selection of the optimal dose of Ii-Key-SARS-CoV-2 Peptide Vaccine (and adjuvant) that produces the strongest, yet safe, immunological response.", "samples": [{"hash": "lXGmkSMIZUP", "uri": "/contracts/lXGmkSMIZUP#milestone-i", "label": "Vaccine Development Agreement (Generex Biotechnology Corp)", "score": 29.8802185059, "published": true}, {"hash": "4VKoADiaOIa", "uri": "/contracts/4VKoADiaOIa#milestone-i", "label": "Vaccine Development Agreement (Nugenerex Immuno-Oncology, Inc.)", "score": 29.8802185059, "published": true}], "snippet_links": [{"key": "phase-i-study", "type": "clause", "offset": [4, 17]}, {"key": "selection-of-the", "type": "clause", "offset": [39, 55]}], "hash": "0f2e4ac972d0bd10eef851171c5b2074", "id": 2}, {"size": 2, "snippet": "Following completion of [\u2020].", "samples": [{"hash": "iwPTDrywX4j", "uri": "/contracts/iwPTDrywX4j#milestone-i", "label": "Agreement for Antibody Discovery and Development (Omeros Corp)", "score": 21.0, "published": true}, {"hash": "h6hWqVzmB38", "uri": "/contracts/h6hWqVzmB38#milestone-i", "label": "Agreement for Antibody Discovery and Development (Omeros Corp)", "score": 21.0, "published": true}], "snippet_links": [{"key": "completion-of", "type": "clause", "offset": [10, 23]}], "hash": "bd4ff0a7c84cb172fa3f5511d8e2a42a", "id": 3}, {"size": 2, "snippet": "means the date on which Company shall have raised an aggregate of Four Million Five Hundred Thousand Dollars ($4,500,000) in equity financing following the Effective Date;", "samples": [{"hash": "lDW9kWbCHNp", "uri": "/contracts/lDW9kWbCHNp#milestone-i", "label": "Employment Agreement (Roughneck Supplies Inc.)", "score": 21.0, "published": true}, {"hash": "7jIi0Rp97vB", "uri": "/contracts/7jIi0Rp97vB#milestone-i", "label": "Employment Agreement (Roughneck Supplies Inc.)", "score": 21.0, "published": true}], "snippet_links": [{"key": "equity-financing", "type": "definition", "offset": [125, 141]}, {"key": "following-the-effective-date", "type": "clause", "offset": [142, 170]}], "hash": "15c059811f123772554a8d38948fd8e9", "id": 4}, {"size": 2, "snippet": "means the initiation of a Phase IIb clinical trial for the Product not later than December 31, 2004.", "samples": [{"hash": "jKf51oJ3Bc", "uri": "/contracts/jKf51oJ3Bc#milestone-i", "label": "Loan Agreement (Corautus Genetics Inc)", "score": 19.0, "published": true}], "snippet_links": [{"key": "phase-iib-clinical-trial", "type": "definition", "offset": [26, 50]}, {"key": "the-product", "type": "definition", "offset": [55, 66]}], "hash": "105a330325f8e7d35887bc926d9387ec", "id": 5}, {"size": 1, "snippet": "The parties agree that the following sub-milestones will be completed by [**]:\n(i) Best shall provide Kronos with: (1) one master copy of the Software (as such Software exists as of the time of delivery) in source code and object code formats, and (2) one electronic and one hard copy of the Documentation related thereto (as such Documentation exists as of the time of delivery);\n(ii) Best shall successfully complete the Regression Test of the build of the original source code, as further described in the Technology Delivery Plan;\n(iii) Best shall make available assistance to Kronos to create and test the Kronos Initial Release as further described in the Technology Delivery Plan and\n(iv) Best shall make available initial training for Kronos' engineers on the design and implementation of the Software, as further described in the Technology Delivery Plan.", "samples": [{"hash": "2xiTQ1sESO5", "uri": "/contracts/2xiTQ1sESO5#milestone-i", "label": "Integration Agreement (Kronos Inc)", "score": 18.0, "published": true}], "snippet_links": [{"key": "the-parties-agree-that", "type": "clause", "offset": [0, 22]}, {"key": "completed-by", "type": "clause", "offset": [60, 72]}, {"key": "copy-of-the-software", "type": "clause", "offset": [130, 150]}, {"key": "the-time-of-delivery", "type": "clause", "offset": [182, 202]}, {"key": "object-code", "type": "clause", "offset": [223, 234]}, {"key": "hard-copy", "type": "clause", "offset": [275, 284]}, {"key": "complete-the", "type": "clause", "offset": [410, 422]}, {"key": "original-source-code", "type": "definition", "offset": [459, 479]}, {"key": "delivery-plan", "type": "clause", "offset": [520, 533]}, {"key": "assistance-to", "type": "clause", "offset": [567, 580]}, {"key": "initial-release", "type": "clause", "offset": [618, 633]}, {"key": "initial-training", "type": "definition", "offset": [722, 738]}, {"key": "implementation-of-the-software", "type": "clause", "offset": [779, 809]}], "hash": "87d17c1e8da31e0cd5ae97ce9a8e4caf", "id": 6}, {"size": 1, "snippet": "Submission/filing, by no later than eighteen (18) months from the Effective Date, of a prototype of Product with TSA, ISA or an equivalent governmental body in any one of the Major Countries for regulatory approval.", "samples": [{"hash": "bpRmF57L9VV", "uri": "/contracts/bpRmF57L9VV#milestone-i", "label": "License Agreement (Traceguard Technologies, Inc.)", "score": 18.0, "published": true}], "snippet_links": [{"key": "from-the-effective-date", "type": "clause", "offset": [57, 80]}, {"key": "governmental-body", "type": "definition", "offset": [139, 156]}, {"key": "major-countries", "type": "definition", "offset": [175, 190]}, {"key": "regulatory-approval", "type": "clause", "offset": [195, 214]}], "hash": "2bd4498b5951f43bbdb0936337883b81", "id": 7}, {"size": 1, "snippet": "means the *** *** *** ***.", "samples": [{"hash": "j4LbQc6st2h", "uri": "/contracts/j4LbQc6st2h#milestone-i", "label": "Leptin Research, Development and License Agreement (Ligand Pharmaceuticals Inc)", "score": 18.0, "published": true}], "snippet_links": [], "hash": "a9dd8ee12eda60471a69939c1ddb992c", "id": 8}, {"size": 1, "snippet": "set forth in Article I, Section 1.01 of the Loan Agreement, shall be deleted and replaced with the following:", "samples": [{"hash": "jKf51oJ3Bc", "uri": "/contracts/jKf51oJ3Bc#milestone-i", "label": "Loan Agreement (Corautus Genetics Inc)", "score": 19.0, "published": true}], "snippet_links": [{"key": "article-i", "type": "clause", "offset": [13, 22]}, {"key": "the-loan-agreement", "type": "clause", "offset": [40, 58]}, {"key": "replaced-with", "type": "clause", "offset": [81, 94]}], "hash": "e4762ef641b27e7e44cac612ccd5846a", "id": 9}, {"size": 1, "snippet": "means [*], and is referred to in Section 5.2(a) hereof.", "samples": [{"hash": "khKPT17eJZ9", "uri": "http://pdf.secdatabase.com/1235/0001032210-02-000744.pdf", "label": "pdf.secdatabase.com", "score": 12.1197805405, "published": false}], "snippet_links": [], "hash": "8960651c77618a3e5dbd13e1f71a1eee", "id": 10}], "next_curs": "ClgSUmoVc35sYXdpbnNpZGVyY29udHJhY3RzcjQLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIUbWlsZXN0b25lLWkjMDAwMDAwMGEMogECZW4YACAA", "definition": {"title": "Milestone I", "size": 22, "snippet": "means the general availability (on iOS, Google/Android and Web) of an updated version of the Truth Social app, with streaming enabled via the Master PoP at 1623 Farnam LLC\u2019s data center in Omaha, NE.", "id": "milestone-i", "examples": ["In the event that the initial stage of either the [*] Research Program or the [*] Research Program yields a Compound that satisfies the criteria set forth in the relevant Research Program for <strong>Milestone I</strong>, Merck, in consultation with Transcell, will determine whether an increased number of chemistry FTE&#x27;s may be required at Merck or Transcell for carrying out the subsequent stages of such Research Program.", "Additionally, Borrower is currently in default under Section 6.7(c) of the Agreement (as in effect prior to the date hereof) due to Borrower\u2019s failure to consummate Equity <strong>Milestone I</strong> (as defined in the Agreement prior to the date hereof) (the \u201cExisting Default\u201d).", "If Client hires i-Showcase to manage the content and data on Client\u2019s website, then i-Showcase start this task after <strong>Milestone I</strong> is achieved.", "Beginning on the date on which Borrower achieves Equity <strong>Milestone I</strong> and continuing at all times thereafter.", "Notwithstanding any provision in this Agreement to the contrary, Seventy-Five Thousand Dollars ($75,000) of the Base Salary shall be accrued and not be paid until Company shall have completed the <strong>Milestone I</strong> (as defined below)(the \u201cAccrued Base Salary\u201d), at which time Company shall (a) pay Executive thereafter his entire Base Salary and (b) pay in lump sum to Executive within thirty (30) days thereafter his Accrued Base Salary.", "Subject to the terms and conditions of this Agreement, beginning on the later of (i) January 1, 2021 and (ii) the achievement of Performance <strong>Milestone I</strong>, and continuing through September 30, 2021 (as such date may be extended in Agent\u2019s sole discretion), Borrower may request and the Lenders shall severally (and not jointly) make an additional Term Loan Advance in a principal amount of Ten Million Dollars ($10,000,000) (the \u201cTranche 2 Advance\u201d).", "The Beneficiary Firm achieved <strong>Milestone I</strong> Completion Certificate as per the Programme Agreement on DD.MM.YYY and received approval from Ministry of Heavy Industries on DD.MM.YYY.", "In the event that the Technical Milestone II Criteria are met and the payment under Section 4.2(b)(i) (Technical <strong>Milestone I</strong>) has not yet been paid to Adimab with respect to such Research Program, iTeos shall also make the payment under Section 4.2(b)(i) (Technical <strong>Milestone I</strong>) simultaneously with the payment under this Section 4.2(b)(ii) (Technical Milestone II).", "For each Knockout Mice Project, DELTAGEN shall submit invoices to SCHERING-PLOUGH for the payments set forth in the Scope of Work and Budget upon DELTAGEN&#x27;s completion of each Milestone set forth in the Scope of Work and Budget (except for <strong>Milestone I</strong> - Construct Generation).", "Participate in kick-off meeting of SAA one week after SAA award (<strong>Milestone I</strong>)."], "related": [["milestone-2", "Milestone 2", "Milestone 2"], ["milestone-1", "Milestone 1", "Milestone 1"], ["milestone-date", "Milestone Date", "Milestone Date"], ["milestone", "Milestone", "Milestone"], ["milestone-event", "Milestone Event", "Milestone Event"]], "related_snippets": [], "updated": "2025-07-12T05:45:48+00:00"}, "json": true, "cursor": ""}}